Apabetalone ( DrugBank: Apabetalone )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 86 | Pulmonary arterial hypertension | 2 |
86. Pulmonary arterial hypertension
Clinical trials : 1,205 / Drugs : 684 - (DrugBank : 124) / Drug target genes : 100 - Drug target pathways : 193
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04915300 (ClinicalTrials.gov) | October 2022 | 19/5/2021 | Apabetalone for Pulmonary Arterial Hypertension | Apabetalone for Pulmonary Arterial Hypertension: a Phase 2 Clinical Study | Pulmonary Arterial Hypertension | Drug: Apabetalone;Drug: Placebo | Laval University | Canadian Institutes of Health Research (CIHR);Resverlogix Corp | Not yet recruiting | 18 Years | 75 Years | All | 72 | Phase 2 | Canada |
| 2 | NCT03655704 (ClinicalTrials.gov) | August 22, 2019 | 28/8/2018 | Apabetalone for Pulmonary Arterial Hypertension: a Pilot Study | Apabetalone for Pulmonary Arterial Hypertension: a Pilot Study | Pulmonary Arterial Hypertension | Drug: Apabetalone | Steeve Provencher | Resverlogix Corp | Completed | 18 Years | 75 Years | All | 7 | Early Phase 1 | Canada |